$2 Billion

Gilead Sciences, Inc.

General Advisory

Financial Advisor, May 2020

Gilead Sciences, Inc.
10-Year Strategic Collaboration with Arcus Biosciences, Inc.

Gilead Sciences, Inc. has entered into a 10-year partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’ pipeline.

Under the terms of the agreement, Arcus will receive $375 million upon closing, consisting of a $175 million upfront payment and a $200 million equity investment from Gilead. Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its current clinical product candidates. As part of the collaboration, Gilead will gain rights to zimberelimab, and will receive the right to opt-in to all other current Arcus clinical candidates, including AB154, AB928, and AB680, upon payment of an opt-in fee that ranges from $200 million to $275 million per program, after delivery of a qualifying data package. If Gilead opts-in to the AB154 program, Arcus is eligible to receive up to $500 million in potential future U.S. regulatory approval milestones for AB154. Gilead will receive the right to opt-in to all other programs that emerge from Arcus’s research portfolio over the next 10 years, upon payment of an opt-in fee of $150 million per program after Arcus’ delivery of a qualifying data package.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in randomized Phase 2 development for first-line treatment of metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, as well as in combinations across the portfolio.

More Like This

Nov 2023

Merger with Neoleukin Therapeutics (Nasdaq:NLTX)

Exclusive Financial Advisor

View Details >
Oct 2018
Ideal Option

Strategic Investment by Varsity Healthcare Partners

Financial Advisor

View Details >
May 2018
Community Medical Services

Recapitalisation by Clearview Capital, LLC

Financial Advisor

View Details >